News

Global Immunotherapy Drugs Market to Hit USD 829.78 Billion by 2032, Driven by Rising Cancer and Autoimmune Disease Cases – SNS Insider
According to Research by SNS Insider, Immunotherapy Drugs Market growth is fueled by increased adoption of monoclonal antibodies, breakthrough innovations in personalized therapies, and expanding ...
Zacks Investment Research on MSN1d
Regeneron to Report Q1 Earnings: What's in Store for the Stock?
Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report first-quarter 2025 results on April 29, 2025. The ...
Targeted Oncology1d
ICIs Effective Regardless of Patients' Age, But Key Immune Phenotype Differences May Enable Tailored Regimens
A study in Nature Communications found that older cancer patients have similar outcomes with immune checkpoint inhibitors as younger patients, despite having different baseline immune profiles, ...
Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)
Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than ...
360Dx6d
Agilent Gains IVDR Certification for Expanded Use of CDx Assay for Keytruda
The PD-L1 IHC 22C3 PharmDx (Code SK006) assay is now certified for use to aid treatment decisions for patients with gastric or gastroesophageal junction adenocarcinoma.